Global Bio CMO Market: Size, Trends & Forecasts (2019-2023 Edition)
SCOPE OF THE REPORT
The report entitled “Global Bio CMO Market: Size, Trends & Forecasts (2019-2023 Edition)”, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration rate, and manufacturing process. A brief segment analysis is provided with their actual and forecasted value. In addition, an analysis of the global biologics market by value, by top selling products, etc. is also mentioned in the report.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global bio CMO has also been forecasted for the years 2019-2023, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Boehringer Ingelheim, Lonza Group AG, Samsung Electronics (Samsung Biologics) and WuXi PharmaTech (Cayman) Inc. (Wuxi Biologics) are the key operating companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Company Coverage
The pharmaceutical industry is a vital component of health care system globally and is mainly comprised of large number of private as well as public organizations that discover, develop, produce, and market drugs for medical use. World’s major pharmaceutical companies are located in the North America, Europe and Japan. On the basis of technological platform, pharmaceutical drugs can be categorized into small molecule or conventional drugs and large molecule or biologic drugs.
Biologics are made through biological processes and are generally injected. Biologics comprises of vaccines, blood or blood components, somatic cells, gene therapy, etc. These are categorized into first-or second generation, depending on development period and cell line. Biosimilars are the biological that are similar, but not identical to the original product.
CMO or Contract Manufacturing Organization is a third party, which the pharmaceutical firms approach for the manufacturing of components of its product or whole of its product. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm Bio CMOs are typically used to provide secondary manufacturing coverage for the branded pharmaceutical industry. On the basis of production technology, bio CMOs can be divided into mammalian cell system and microbial system.
The global bio CMO market has witnessed stable growth in the past few years and is expected to grow at a healthy rate during the forecasted period (2019-2023), the market is anticipated to further propel with a poised growth rate. The growth of global bio CMO market would be supported by the growth drivers such as rising pharmaceutical industry, growth in biosimilar industry, rise in drug approvals etc. However, the growth of global bio CMO market is being obstructed by numerous challenges such as, lack of technology, security and knowledge, inappropriate methods followed by CMOs etc.
The report entitled “Global Bio CMO Market: Size, Trends & Forecasts (2019-2023 Edition)”, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration rate, and manufacturing process. A brief segment analysis is provided with their actual and forecasted value. In addition, an analysis of the global biologics market by value, by top selling products, etc. is also mentioned in the report.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global bio CMO has also been forecasted for the years 2019-2023, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Boehringer Ingelheim, Lonza Group AG, Samsung Electronics (Samsung Biologics) and WuXi PharmaTech (Cayman) Inc. (Wuxi Biologics) are the key operating companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Company Coverage
- Lonza Group AG
- Boehringer Ingelheim
- Samsung Electronics (Samsung Biologics)
- WuXi PharmaTech (Cayman) Inc. (Wuxi Biologics)
The pharmaceutical industry is a vital component of health care system globally and is mainly comprised of large number of private as well as public organizations that discover, develop, produce, and market drugs for medical use. World’s major pharmaceutical companies are located in the North America, Europe and Japan. On the basis of technological platform, pharmaceutical drugs can be categorized into small molecule or conventional drugs and large molecule or biologic drugs.
Biologics are made through biological processes and are generally injected. Biologics comprises of vaccines, blood or blood components, somatic cells, gene therapy, etc. These are categorized into first-or second generation, depending on development period and cell line. Biosimilars are the biological that are similar, but not identical to the original product.
CMO or Contract Manufacturing Organization is a third party, which the pharmaceutical firms approach for the manufacturing of components of its product or whole of its product. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm Bio CMOs are typically used to provide secondary manufacturing coverage for the branded pharmaceutical industry. On the basis of production technology, bio CMOs can be divided into mammalian cell system and microbial system.
The global bio CMO market has witnessed stable growth in the past few years and is expected to grow at a healthy rate during the forecasted period (2019-2023), the market is anticipated to further propel with a poised growth rate. The growth of global bio CMO market would be supported by the growth drivers such as rising pharmaceutical industry, growth in biosimilar industry, rise in drug approvals etc. However, the growth of global bio CMO market is being obstructed by numerous challenges such as, lack of technology, security and knowledge, inappropriate methods followed by CMOs etc.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Pharmaceutical Industry Overview
2.1.1 Segments of Pharmaceutical Industry (Drugs)
2.2 Biotechnology/Biologics Overview
2.3 Biosimilar Overview
2.4 Biologics/ Biosimilar Manufacturing
2.5 Bio CMO Overview
2.5.1 Comparison: In-House Vs CMO Production
3. GLOBAL MARKET ANALYSIS
3.1 Global Biologics Market Analysis
3.1.1 Global Biologics Market by Value
3.1.2 Global Biologics Market by Top Selling Drugs
3.2 Global Biologics Manufacturing Market Analysis
3.2.1 Global Biologics Manufacturing Market by Value
3.2.2 Global Biologics Manufacturing Market by Segments (In-house and CMO)
3.3 Global Bio CMO Market Analysis
3.3.1 Global Bio CMO Market by Value
3.3.2 Global Bio CMO Market by Penetration Rate
3.3.3 Global Bio CMO Market by Capacity
3.3.4 Global Bio CMO Market by Manufacturing Processes (Downstream, Upstream and Fill & Finish process)
3.4 Global Bio CMO Market Segment Analysis
3.4.1 Global Bio CMO Downstream Process Market by Value
3.4.2 Global Bio CMO Upstream Process Market by Value
3.4.3 Global Bio CMO Fill and Finish Process Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Pharmaceuticals Industry
4.1.2 Surging Geriatric Population
4.1.3 Growth in Biosimilar Industry
4.1.4 Preference of Biologics over Small Molecules
4.2 Challenges
4.2.1 Lack of Technology, Security and Knowledge
4.2.2 Inappropriate Methods Followed by CMOs
4.3 Market Trends
4.3.1 Surging Pharmaceuticals Outsourcing Rate
4.3.2 Capacity Utilization Rate of CMO Industry
4.3.3 Growth in Mammalian Cell Structure
5. COMPETITIVE LANDSCAPE
5.1 Global Bio CMO Market Players: A Financial Comparison
5.2 Global Biologics Outsourcing Market Share by Players
6. COMPANY PROFILE
6.1 Lonza Group AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Boehringer Ingelheim
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Samsung Electronics (Samsung BioLogics)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 WuXi PharmaTech (Cayman) Inc. (Wuxi Biologics)
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
2. INTRODUCTION
2.1 Pharmaceutical Industry Overview
2.1.1 Segments of Pharmaceutical Industry (Drugs)
2.2 Biotechnology/Biologics Overview
2.3 Biosimilar Overview
2.4 Biologics/ Biosimilar Manufacturing
2.5 Bio CMO Overview
2.5.1 Comparison: In-House Vs CMO Production
3. GLOBAL MARKET ANALYSIS
3.1 Global Biologics Market Analysis
3.1.1 Global Biologics Market by Value
3.1.2 Global Biologics Market by Top Selling Drugs
3.2 Global Biologics Manufacturing Market Analysis
3.2.1 Global Biologics Manufacturing Market by Value
3.2.2 Global Biologics Manufacturing Market by Segments (In-house and CMO)
3.3 Global Bio CMO Market Analysis
3.3.1 Global Bio CMO Market by Value
3.3.2 Global Bio CMO Market by Penetration Rate
3.3.3 Global Bio CMO Market by Capacity
3.3.4 Global Bio CMO Market by Manufacturing Processes (Downstream, Upstream and Fill & Finish process)
3.4 Global Bio CMO Market Segment Analysis
3.4.1 Global Bio CMO Downstream Process Market by Value
3.4.2 Global Bio CMO Upstream Process Market by Value
3.4.3 Global Bio CMO Fill and Finish Process Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Pharmaceuticals Industry
4.1.2 Surging Geriatric Population
4.1.3 Growth in Biosimilar Industry
4.1.4 Preference of Biologics over Small Molecules
4.2 Challenges
4.2.1 Lack of Technology, Security and Knowledge
4.2.2 Inappropriate Methods Followed by CMOs
4.3 Market Trends
4.3.1 Surging Pharmaceuticals Outsourcing Rate
4.3.2 Capacity Utilization Rate of CMO Industry
4.3.3 Growth in Mammalian Cell Structure
5. COMPETITIVE LANDSCAPE
5.1 Global Bio CMO Market Players: A Financial Comparison
5.2 Global Biologics Outsourcing Market Share by Players
6. COMPANY PROFILE
6.1 Lonza Group AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Boehringer Ingelheim
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Samsung Electronics (Samsung BioLogics)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 WuXi PharmaTech (Cayman) Inc. (Wuxi Biologics)
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
LIST OF FIGURES
Figure 1: History of Pharmaceutical Industry
Figure 2: Pharmaceutical Industry Segments
Figure 3: Global Biologics Market by Value; 2016-2018 (US$ Billion)
Figure 4: Global Biologics Market by Value; 2019-2023 (US$ Billion)
Figure 5: Global Biologics Manufacturing Market by Value; 2014-2018 (US$ Billion)
Figure 6: Global Biologics Manufacturing Market by Value; 2019-2023 (US$ Billion)
Figure 7: Global Biologics Manufacturing Market by Segments; 2018 (Percentage, %)
Figure 8: Global Bio CMO Market by Value; 2014-2018 (US$ Billion)
Figure 9: Global Bio CMO Market by Value; 2019-2023 (US$ Billion)
Figure 10: Global Bio CMO Market by Penetration Rate; 2014-2018 (Percentage, %)
Figure 11: Global Bio CMO Market by Penetration Rate; 2019-2023 (Percentage, %)
Figure 12: Global Bio CMO Market by Capacity; 2014-2018 (KL)
Figure 13: Global Bio CMO Market by Capacity; 2019-2023 (KL)
Figure 14: Global Bio CMO Market by Manufacturing Processes; 2018 (Percentage, %)
Figure 15: Global Bio CMO Downstream Process Market by Value; 2014-2018 (US$ Billion)
Figure 16: Global Bio CMO Downstream Process Market by Value; 2019-2023 (US$ Billion)
Figure 17: Global Bio CMO Upstream Process Market by Value; 2014-2018 (US$ Billion)
Figure 18: Global Bio CMO Upstream Process Market by Value; 2019-2023 (US$ Billion)
Figure 19: Global Bio CMO Fill and Finish Process Market by Value; 2014-2018 (US$ Billion)
Figure 20: Global Bio CMO Fill and Finish Process Market by Value; 2019-2023 (US$ Billion)
Figure 21: Global Pharmaceuticals Market Value; 2018-2023 (US$ Trillion)
Figure 22: Global Ageing Population; 2017-2050 (Million)
Figure 23: Global Biosimilar Market Value; 2018-2023 (US$ Billion)
Figure 24: Global Biopharmaceuticals (Drugs) Market by Segments; 2015-2022 (Percentage, %)
Figure 25: Big Pharmaceuticals Outsourcing Rate; 2015-2020 (Percentage, %)
Figure 26: Capacity Utilization Rate of the Global CMO Industry; 2014-2020 (Percentage, %)
Figure 27: Global Biologics Outsourcing Market Share by Players; 2018 (Percentage, %)
Figure 28: Lonza Group AG Sales; 2014-2018 (US$ Billion)
Figure 29: Lonza Group AG Sales by Segments; 2018 (Percentage, %)
Figure 30: Lonza Group AG Sales by Region; 2018 (Percentage, %)
Figure 31: Boehringer Ingelheim Net Sales; 2014-2018 (US$ Billion)
Figure 32: Boehringer Ingelheim Net Sales by Segments; 2018 (Percentage, %)
Figure 33: Boehringer Ingelheim Net Sales by Region; 2018 (Percentage, %)
Figure 34: Samsung Electronics Segments Overview
Figure 35: Samsung Electronics Ownership Structure
Figure 36: Samsung BioLogics Revenue; 2014-2018 (US$ Million)
Figure 37: Wuxi Biologics Revenue; 2014-2018 (US$ Million)
Figure 38: Wuxi Biologics Revenue by Services; 2018 (Percentage, %)
Figure 39: Wuxi Biologics Revenue by Region; 2018 (Percentage, %)
Table 1: Chemical Drugs v/s 1st Generation Biologics v/s 2nd Generation Biologics
Table 2: US Approved Biosimilars
Table 3: Comparison: In-House Vs CMO Production
Table 4: Top Selling Biologic Drugs; 2018
Table 5: Global Bio CMO Market Players: A Financial Comparison; 2018
Figure 1: History of Pharmaceutical Industry
Figure 2: Pharmaceutical Industry Segments
Figure 3: Global Biologics Market by Value; 2016-2018 (US$ Billion)
Figure 4: Global Biologics Market by Value; 2019-2023 (US$ Billion)
Figure 5: Global Biologics Manufacturing Market by Value; 2014-2018 (US$ Billion)
Figure 6: Global Biologics Manufacturing Market by Value; 2019-2023 (US$ Billion)
Figure 7: Global Biologics Manufacturing Market by Segments; 2018 (Percentage, %)
Figure 8: Global Bio CMO Market by Value; 2014-2018 (US$ Billion)
Figure 9: Global Bio CMO Market by Value; 2019-2023 (US$ Billion)
Figure 10: Global Bio CMO Market by Penetration Rate; 2014-2018 (Percentage, %)
Figure 11: Global Bio CMO Market by Penetration Rate; 2019-2023 (Percentage, %)
Figure 12: Global Bio CMO Market by Capacity; 2014-2018 (KL)
Figure 13: Global Bio CMO Market by Capacity; 2019-2023 (KL)
Figure 14: Global Bio CMO Market by Manufacturing Processes; 2018 (Percentage, %)
Figure 15: Global Bio CMO Downstream Process Market by Value; 2014-2018 (US$ Billion)
Figure 16: Global Bio CMO Downstream Process Market by Value; 2019-2023 (US$ Billion)
Figure 17: Global Bio CMO Upstream Process Market by Value; 2014-2018 (US$ Billion)
Figure 18: Global Bio CMO Upstream Process Market by Value; 2019-2023 (US$ Billion)
Figure 19: Global Bio CMO Fill and Finish Process Market by Value; 2014-2018 (US$ Billion)
Figure 20: Global Bio CMO Fill and Finish Process Market by Value; 2019-2023 (US$ Billion)
Figure 21: Global Pharmaceuticals Market Value; 2018-2023 (US$ Trillion)
Figure 22: Global Ageing Population; 2017-2050 (Million)
Figure 23: Global Biosimilar Market Value; 2018-2023 (US$ Billion)
Figure 24: Global Biopharmaceuticals (Drugs) Market by Segments; 2015-2022 (Percentage, %)
Figure 25: Big Pharmaceuticals Outsourcing Rate; 2015-2020 (Percentage, %)
Figure 26: Capacity Utilization Rate of the Global CMO Industry; 2014-2020 (Percentage, %)
Figure 27: Global Biologics Outsourcing Market Share by Players; 2018 (Percentage, %)
Figure 28: Lonza Group AG Sales; 2014-2018 (US$ Billion)
Figure 29: Lonza Group AG Sales by Segments; 2018 (Percentage, %)
Figure 30: Lonza Group AG Sales by Region; 2018 (Percentage, %)
Figure 31: Boehringer Ingelheim Net Sales; 2014-2018 (US$ Billion)
Figure 32: Boehringer Ingelheim Net Sales by Segments; 2018 (Percentage, %)
Figure 33: Boehringer Ingelheim Net Sales by Region; 2018 (Percentage, %)
Figure 34: Samsung Electronics Segments Overview
Figure 35: Samsung Electronics Ownership Structure
Figure 36: Samsung BioLogics Revenue; 2014-2018 (US$ Million)
Figure 37: Wuxi Biologics Revenue; 2014-2018 (US$ Million)
Figure 38: Wuxi Biologics Revenue by Services; 2018 (Percentage, %)
Figure 39: Wuxi Biologics Revenue by Region; 2018 (Percentage, %)
Table 1: Chemical Drugs v/s 1st Generation Biologics v/s 2nd Generation Biologics
Table 2: US Approved Biosimilars
Table 3: Comparison: In-House Vs CMO Production
Table 4: Top Selling Biologic Drugs; 2018
Table 5: Global Bio CMO Market Players: A Financial Comparison; 2018
